The use of day-and-night hybrid closed-loop insulin delivery improves glycaemic control while reducing the risk of hypoglycaemia in adults, adolescents, and children with type 1 diabetes compared with conventional pump therapy or sensor-augmented pump therapy. The gene discussed is INS; the disease is type 1 diabetes mellitus.